100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
733043-41-9Anagrelide 3-Hydroxy Impurity
● In Stock
| Catalogue No.: | VL2810006 |
|---|---|
| CAS No.: | 733043-41-9 |
| Mol. Formula: | C10H7Cl2N3O2 |
| Mol. Weight: | 272.09 |
Additional information on CAS 733043-41-9
Parent drug
AnagrelideIUPAC Name
6,7-Dichloro-1,5-dihydro-3-hydroxyimidazo[2,1-b]quinazolin-2(3H)-onePharmacopoeial Synonyms
N/AOther Synonyms
6,7-dichloro-3-hydroxy-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-oneSmiles
O=C1NC2=NC3=C(C(Cl)=C(Cl)C=C3)CN2C1OInchl
InChI=1S/C10H7Cl2N3O2/c11-5-1-2-6-4(7(5)12)3-15-9(17)8(16)14-10(15)13-6/h1-2,9,17H,3H2,(H,13,14,16)Description
Anagrelide 3-Hydroxy Impurity, CAS 733043-41-9, is a related substance of anagrelide arising from oxidative hydroxylation at the 3-position of the heteroaromatic scaffold. The molecular formula is C10H7Cl2N3O2 and the molecular weight is 272.09. As a chlorinated N-heterocyclic impurity, it is relevant to impurity profiling and degradation pathway assessment under stability-indicating studies. Structural assignment and quantification typically require LC-MS/MS, high-resolution LC-MS, and orthogonal HPLC methods with UV detection. In a regulatory context, it may be evaluated within ICH Q3A and, where applicable, ICH M7 frameworks when impurity fate, carryover, and toxicological significance are investigated.References
Birgegård, Gunnar. “The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.†Current Hematologic Malignancy Reports, vol. 11, no. 5, 6 Aug. 2016, pp. 348–355, www.ncbi.nlm.nih.gov/pmc/articles/PMC5031713/, 10.1007/s11899-016-0335-0.Request a Quote
"*" indicates required fields
Other products related to Anagrelide impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
